Navigation Links
Enox Biopharma Will Present Its Unique Self-Sterilizing Urinary Catheter at the 49th Annual ICAAC Meeting.

VANCOUVER, British Columbia, Sept. 11 /PRNewswire/ -- Enox Biopharma, Inc., a medical-device company, dedicated to the commercializing of a unique drug eluting technology for preventing microbial infections associated with certain medical devices, announced today that it will present full details of the successful development of the self-sterilizing urinary catheters at the 2009 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) which convenes in San Francisco, September 12-15. The world's largest convention of its kind, the ICAAC brings together more than 10,000 physicians, researchers and other healthcare professionals to foster worldwide solutions to the problem of infectious diseases.

At ICAAC, Dr. Gilly Regev-Shoshani, a UBC research associate working on this project, and Dr. Chris Miller, a UBC clinical assistant professor and a director of Enox, will present data outlining the Enox urinary catheter's ability to slowly release nitric oxide into a solution over the course of two weeks. The result: a self-sterilizing process, which prevents biofilm formation on the catheter, inhibits bacterial growth in the area immediately surrounding the catheter without lingering within the body. Nitric oxide exhibits strong activity against a wide range of pathogens and is part of the body's innate response to infections. Enox's innovative approach addressing hospital acquired infections offers significant advantages over other antiseptic coating or drug eluting technologies. Nitric oxide releasing catheters are less toxic to the human body; they remain effective over a longer period of time; and they present limited risk, if any, to developing antibiotic resistance to various bacterial strains.

Enox's First Product, a Self-Sterilizing Urinary Catheter

A team lead by Professor Yossef Av-Gay , of the Faculty of Medicine, University of British Columbia and the Founder and CEO of Enox, has developed a patented, self-sterilizing catheter that, in a controlled process, slowly releases small amounts of nitric oxide gas molecules. Nitric oxide prevents biofilm formation and bacterial growth, addressing a growing concern: catheter-associated urinary infection which is the most common hospital acquired infection, affecting over one million people annually in the U.S. alone.

Hospital acquired infections are critically interconnected with the increasing threat of antimicrobial resistance. They are frequently caused by bacteria that have become resistant to multiple antibiotics. More than half of these infections are attributed to the use of in-dwelling medical devices such as urinary catheters. Hospital acquired infections can be formed when bacteria attach themselves to medical devices, including urinary catheters, forming microbial biofilms that are particularly adept at developing drug resistance. With the heightened attention to this problem, medical professionals have been developing various strategies to lower the rates of infections without being compelled to reduce the number of devices used.

Safe Harbor Statement

This press release contains certain forward-looking statements. Forward-looking statements may include our statements regarding our goals, beliefs, strategies, objectives, plans, including product and service developments, future financial conditions, results or projections or current expectations. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause actual results to be materially different from those contemplated by the forward-looking statements. Further information on potential factors that could affect our business is described under the heading "Risks Related to Our Business" in Part I, Item 1, "Description of Business" of our Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and in our registration statement on Form S-1 no. 333-154763, which was declared effective on October 31, 2008. Except as otherwise required by law, Enox Biopharma, Inc. undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

    Enox Biopharma, Inc.
    +1 (604) 637-9744

SOURCE Enox Biopharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Helix BioPharma Closes Private Placement
2. PDL BioPharma Provides Third Quarter 2009 Revenue Guidance of Approximately $71 Million
3. Helix BioPharma Announces $13.5 Million Private Placement
4. Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
5. DOR BioPharma to Present at the Rodman & Renshaw Annual Global Investor Healthcare Conference
6. Eiger BioPharmaceuticals Appoints Paul Truex to Board of Directors
7. DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments
8. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
10. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
11. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... ... of automation systems, material handling solutions and components, is opening its latest Parker ... State Street, the facility is Exotic’s second major expansion in Metropolitan Detroit in ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... educational opportunities for school age children in the areas of Science, Technology, Engineering ... sectors of the national economy, and the program aims to increase the number ...
(Date:10/12/2015)... , Oct.12, 2015  MiMedx Group, Inc. (NASDAQ: ... amniotic tissue and patent-protected processes to develop and market ... Orthopedic, Spine, Sports Medicine, Ophthalmic, and the Dental sectors ... had been filed against the Company has been dismissed ... , Chairman and CEO, stated, "As we suspected, this ...
(Date:10/12/2015)... 12 de octubre de 2015 El 8 ... a un récord en el congreso con su declaración ... la International Plasma Awareness Week (IPAW), que se celebrará ... patrocinada por la Plasma Protein Therapeutics Association ... , Aumentar la concienciación mundial acerca de ...
Breaking Biology Technology:
(Date:10/12/2015)... Research and Markets ( ) has announced the ... Market Shares, Strategies, and Forecasts, Worldwide, 2015-2021" to ... --> The study is designed to give a ... a selection from the mountains of data available of ... made by the most senior analysts. Commentary on every ...
(Date:10/12/2015)... , October 12, 2015 NXTD ) ... the growing mobile commerce market, reports on the recent SNS ... . --> NXTD ) ("NXT-ID" or the ... commerce market, reports on the recent SNS Future in Review ... --> NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ...
(Date:10/9/2015)... 2015 ... "Samsung Galaxy S6 Fingerprint Sensor - ... offering. --> ) has ... Galaxy S6 Fingerprint Sensor - Reverse Costing ... --> Research and Markets ( ...
Breaking Biology News(10 mins):